about
Postantibiotic effects of antituberculosis agents alone and in combinationDeletion of the Mycobacterium tuberculosis alpha-crystallin-like hspX gene causes increased bacterial growth in vivoThe bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.The burden of drug-resistant tuberculosis and mechanisms for its control.New drugs in respiratory disorders: II.Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.Short course chemotherapy for tuberculous lymphadenitis in children.A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosetsConsidering the role of four months of rifampin in the treatment of latent tuberculosis infection.Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of CaseumUsing automated pharmacy records to assess the management of tuberculosisTuberculosis of the prostate and urethra: A review.Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application.Management of multidrug-resistant tuberculosis: an update.New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy.Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance.In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosisPhenotypic resistance in mycobacteria: is it because I am old or fat that I resist you?Assessment of the Efficacy of New Anti-Tuberculosis Drugs.Trends in tuberculosis.Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance.MDR-/XDR-TB management: what it was, current standards and what is ahead.Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment: Insights from a hybrid multiscale cellular automaton model.Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
P2860
Q28364143-476DF35D-7BFD-4B3E-B1E8-C38A2E566B9FQ28487051-C67D06AA-51FB-4226-A720-446F8CEEB4FFQ34222223-C9D64B7A-FC9D-44D0-A22D-D42C2EED95DFQ34272283-B584027A-B135-43EB-B457-1E756AD70D73Q34497340-6B82721C-5044-445A-A1F4-A2B8676F7A97Q34991833-6350C602-B29A-4BB3-9963-7682684D830DQ35166484-022DDCF2-657E-44E5-BE17-9BD5D0C15E88Q35191529-055433A8-21D2-4EFD-A5E3-F24D7CB990BDQ35745991-86709690-788B-4FE5-AFD2-ED489CF38CDFQ35857278-34285267-7A92-4F6B-8D0A-7A7B50D9EA31Q36571928-AAC36B13-9F87-4B68-82C4-431FEEED8E17Q36571981-60B0FDFB-DC15-4016-A4F0-45827FE9E780Q37093759-C48D64F3-BA01-4D9E-81F0-EE2E34FF4A4CQ37197737-33C49CC5-9931-4881-B550-972C67153EEBQ37700067-F7387A0D-984E-4E86-BF93-9CD44B0C240AQ37730293-ED387CDB-181C-49A1-A91A-0E248E3AC56AQ37996998-8B30D141-6B05-4457-8084-BAC89B0EFB25Q38236719-33D17CE3-D148-46DD-8A3E-44692945B225Q39501282-0792CADB-B53F-4E18-8AD0-8B38F564CEDEQ39769344-5073EF6A-B9D9-48B9-BE45-901199280F56Q40225626-A003598A-2862-4F90-98AD-491AD378ECBBQ40284952-ECE74CE7-9CC9-4611-92FF-B607424DE1A9Q40410686-86E9BAF3-D3F7-4B92-957D-3D25BE2FD26DQ40749409-6D00B043-45BD-42AF-99C8-810224AB9B0CQ41572870-3B7C8978-F27C-442B-B41A-74BB109A0627Q41768132-CD41A0DB-56D1-4085-AFEA-AB7DC05B95D6Q41820130-BE5A55B0-35E8-462B-9CD6-6C9F3EA7D787Q46273107-2E5C4578-C68F-4223-AECE-B3C6A843E66DQ52663222-6BAFED18-250E-4BB8-99BE-C2FE815083B5Q57276328-1D9FA621-6BE4-48BC-AB3C-7C4065CA6FC0
P2860
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Whither short-course chemotherapy?
@en
type
label
Whither short-course chemotherapy?
@en
prefLabel
Whither short-course chemotherapy?
@en
P1476
Whither short-course chemotherapy?
@en
P2093
P304
P356
10.1016/0007-0971(81)90022-X
P577
1981-10-01T00:00:00Z